August 16, 2018

Verseon Corporation (“Verseon” or the “Company”)

Change of Adviser

Fremont, Calif.—Verseon Corporation (AIM:VSN), a technology-based pharmaceutical company employing a computer-driven platform to develop a diverse drug pipeline, today announces the appointment of Arden Partners plc as nominated adviser and joint broker to the Company with immediate effect.


For further information please contact:

Verseon Corporation
Sebastian Wykeham +1 (510) 225 9000
Arden Partners (NOMAD and Broker)
Ruari McGirr / Maria Gomez De Olea +44 (0) 20 7614 5900
Cantor Fitzgerald Europe (Joint Broker)  
Marc Milmo / Phil Davies +44 (0) 20 7894 7000

For financial and business media enquiries, please contact:

Buchanan Communications Ltd (PR Advisors)
Henry Harrison-Topham / Jamie Hooper +44 (0) 20 7466 5000

About Verseon

Verseon Corporation (, AIM:VSN) is a technology-based pharmaceutical company that pairs a proprietary, computational drug discovery platform with a comprehensive in-house chemistry and biology workflow to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.

Our pledge

Verseon is committed to growth through innovation, building value for its shareholders while respecting its responsibilities as a good corporate citizen